Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank the patients, their families, and the participating study coordinators and support staff for their contributions to the study. The authors thank WriteSource Medical Pty Ltd, Sydney, Australia, for providing medical writing and editing support. Medical writing support was funded by F. Hoffman-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Disclosure statement

ND has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Abbvie, Hanmi, Trovagene, FATE Therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck Labs, and Agios. BAJ (over the past 36 months) has served as a consultant/advisor for AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; received travel reimbursement from AbbVie; and received research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo Oncology, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. BCM and UP are employees of Genentech, Inc. MY is an employee of F. Hoffmann-La Roche Ltd.

Data availability statement

Research data are not shared. Given the small study population the data cannot be adequately anonymized to give an acceptably low risk of patient-re identification. For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing

Additional information

Funding

The study was sponsored by F.Hoffmann-La Roche Ltd.